Talphera Inc (TLPH)

Currency in USD
1.2050
+0.0050(+0.42%)
Real-time Data·
TLPH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.18901.2400
52 wk Range
0.39741.5700
Key Statistics
Prev. Close
1.2
Open
1.19
Day's Range
1.189-1.24
52 wk Range
0.3974-1.57
Volume
374.75K
Average Volume (3m)
313.21K
1-Year Change
178.6127%
Book Value / Share
0.28
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TLPH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.1667
Upside
+162.79%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Talphera Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 3.1667
(+162.79% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy3.00+148.96%-MaintainAug 13, 2026
H.C. Wainwright
Buy---New CoverageJun 05, 2026
WestPark Capital
Buy---New CoverageApr 30, 2026

Talphera Inc Earnings Call Summary for Q2/2026

  • Q2 loss of $0.06/share met estimates; stock fell 4.76% to $1.40, down another 0.71% after-hours despite 249.75% gain over past year.
  • NEPHRO-CRRT trial 75% enrolled with all sites active; top-line data expected 4-5 weeks post-enrollment, PMA filing targeted H1 2027.
  • Cash operating expenses rose 5.4% to $3.9M; $17.1M cash plus $16M conditional financing expected to fund operations through PMA approval.
  • Company raised U.S. CRRT procedure estimate 21% to 200,000 annually for 2027, expanding addressable market for nafamostat launch.
  • Safety review found no new risks; management plans small, education-focused commercial team post-PMA submission with mid-2027 approval target.
Last Updated: 2026-08-12, 05:16 p/m
Read Full Transcript

Earnings

Latest Release
Aug 12, 2026
EPS / Forecast
-0.06 / -0.06
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

TLPH Income Statement

Compare TLPH to Peers and Sector

Metrics to compare
TLPH
Peers
Sector
Relationship
P/E Ratio
−4.1x−6.9x−0.3x
PEG Ratio
−0.100.250.00
Price/Book
4.3x4.6x2.6x
Price / LTM Sales
62,546.5x13.4x3.1x
Upside (Analyst Target)
150.0%38.8%49.0%
Fair Value Upside
Unlock−9.2%6.3%Unlock

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Employees
12

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.29M2.49%1.55M
Other Institutional Investors
42.86M82.57%51.43M
Public Companies & Retail Investors
7.75M14.93%9.30M
Total
51.9M100.00%62.28M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
CorMedix Inc.17.52%9,090,90910,909
AIGH Investment Partners8.98%4,661,5025,594

People Also Watch

27.63
BFb
+0.18%
0.511
ATYR
-1.43%
99.78
ZBH
+1.60%
3.6450
GLBS
-0.68%
31.490
CPRX
+0.03%

FAQ

What Is the Talphera (TLPH) Stock Price Today?

The Talphera stock price today is 1.2050 USD.

What Stock Exchange Does Talphera Trade On?

Talphera is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Talphera?

The stock symbol for Talphera is "TLPH."

What Is the Talphera Market Cap?

As of today, Talphera market cap is 62.5500M USD.

What Is Talphera's Earnings Per Share (TTM)?

The Talphera EPS (TTM) is -0.2373.

When Is the Next Talphera Earnings Date?

Talphera will release its next earnings report on Nov 16, 2026.

From a Technical Analysis Perspective, Is TLPH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Talphera Stock Split?

Talphera has split 1 times.

How Many Employees Does Talphera Have?

Talphera has 12 employees.

What is the current trading status of Talphera (TLPH)?

As of Aug 18, 2026, Talphera (TLPH) is trading at a price of 1.2050 USD, with a previous close of 1.2000 USD. The stock has fluctuated within a day range of 1.1890 USD to 1.2400 USD, while its 52-week range spans from 0.3974 USD to 1.5700 USD.

What Is Talphera (TLPH) Price Target According to Analysts?

The average 12-month price target for Talphera is 3.1667 USD, with a high estimate of 3.5 USD and a low estimate of 3 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +162.79% Upside potential.

What Is the TLPH Premarket Price?

TLPH's last pre-market stock price is 1.1800 USD. The pre-market share volume is 5,710.0000, and the stock has decreased by -0.0200, or -1.6700%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.